Absolute and Relative Contraindications of Pitolisant
Pitolisant has only two absolute contraindications: known hypersensitivity to pitolisant or any component of the formulation (including anaphylaxis), and severe hepatic impairment (Child-Pugh Class C). 1
Absolute Contraindications
- Known hypersensitivity to pitolisant or any formulation component - Anaphylaxis has been reported in treated patients 1
- Severe hepatic impairment (Child-Pugh Class C) - Pitolisant is extensively metabolized by the liver, and there is significant increase in drug exposure in patients with moderate hepatic impairment, making severe impairment an absolute contraindication 1
Relative Contraindications and High-Risk Situations Requiring Avoidance
While not formally listed as absolute contraindications, pitolisant should be avoided in several clinical scenarios where the risk substantially outweighs benefit:
Cardiac Risk Factors
Pitolisant prolongs the QT interval and should be avoided in patients with: 1
- Known QT prolongation
- History of cardiac arrhythmias
- Symptomatic bradycardia
- Hypokalemia or hypomagnesemia
- Congenital long QT syndrome
- Concomitant use with other QT-prolonging drugs
End-Stage Renal Disease
Pitolisant is not recommended in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²) due to significantly increased drug exposure and QT prolongation risk 1
Situations Requiring Dose Modification (Not Contraindications)
Moderate Hepatic Impairment (Child-Pugh Class B)
- Requires reduced dosing: maximum 17.8 mg daily in adults, 8.9 mg in pediatric patients <40 kg 1
- Monitor for increased QTc prolongation 1
Moderate to Severe Renal Impairment (eGFR <60 mL/min/1.73 m²)
- Requires reduced dosing: maximum 17.8 mg daily in adults 1
- Monitor for increased QTc prolongation due to higher drug concentrations 1
CYP2D6 Poor Metabolizers
- Maximum dose 17.8 mg daily in adults, 8.9 mg in pediatric patients <40 kg 1
Concomitant Strong CYP2D6 Inhibitors
- Reduce dose by half or limit maximum to 17.8 mg daily 1
Special Population Warnings
Pregnancy and Breastfeeding
Based on animal data, pitolisant may cause fetal harm, though human data are insufficient. 2 The American Academy of Sleep Medicine guidelines specifically note that "the balance of risks and harms is likely different for pregnant and breastfeeding women" 2
Pitolisant reduces the effectiveness of oral contraceptives - patients must use alternative non-hormonal contraceptive methods during treatment and for at least 21 days after discontinuation 1
Clinical Pitfalls to Avoid
Do not assume mild-moderate renal or hepatic impairment is safe at standard doses - these patients require dose reduction AND monitoring for QT prolongation 1
Screen for electrolyte abnormalities before initiating - hypokalemia and hypomagnesemia increase torsade de pointes risk with QT-prolonging drugs 1
Review all concomitant medications for QT-prolonging effects - the combination substantially increases arrhythmia risk 1
Counsel all women of childbearing potential about contraceptive failure risk - hormonal contraceptives will be less effective, requiring backup methods 1